In total, 27 patients (56% male and 44% female) with stage III (41%) and IV (59%) melanoma who showed locoregional progression under previous immunotherapy with PD-1-inhibitors were included in this retrospective study as depicted in Table 1 and Table S1. The gene discussed is PDCD1; the disease is melanoma.